PRECIGEN, INC. (PGEN)
D
Pipeline Grade
Financial Position (from SEC Filings)
$7.5M
Cash & Equivalents
$43.8M
Quarterly Burn Rate
1 mo
Est. Cash Runway
$1,569M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06538480 | Zopa Retreatment and Vector Shedding in Adults With RRP | PHASE4 | Recruiting | 30 |
| NCT06157151 | PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer | PHASE2 | Recruiting | 24 |
| NCT04724980 | Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis | PHASE2 | Active Not Recruiting | 38 |
| NCT03927261 | PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS | PHASE1 | Active Not Recruiting | 88 |
| NCT03907527 | Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian,... | PHASE1 | Active Not Recruiting | 71 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.